These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 1295414)
21. Effect of CAPD and hemodialysis on parathyroid function. Malberti F; Corradi B; Imbasciati E Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912 [TBL] [Abstract][Full Text] [Related]
22. Prevalence and pattern of renal bone disease in end stage renal disease patients in Ile-Ife, Nigeria. Sanusi AA; Arogundade FA; Oladigbo M; Ogini LM; Akinsola A West Afr J Med; 2010; 29(2):75-80. PubMed ID: 20544630 [TBL] [Abstract][Full Text] [Related]
23. Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis. Malluche HH; Faugere MC; Fanti P; Price PA Kidney Int; 1984 Dec; 26(6):869-74. PubMed ID: 6335905 [TBL] [Abstract][Full Text] [Related]
24. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ]. Jarava C; Armas JR; Palma A Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651 [TBL] [Abstract][Full Text] [Related]
25. The clinical spectrum of renal osteodystrophy in 57 chronic hemodialysis patients: a correlation between biochemical parameters and bone pathology findings. Chazan JA; Libbey NP; London MR; Pono L; Abuelo JG Clin Nephrol; 1991 Feb; 35(2):78-85. PubMed ID: 2019018 [TBL] [Abstract][Full Text] [Related]
26. Assessment of renal osteodystrophy in hemodialysis patients. DeVita MV; Rasenas LL; Bansal M; Gleim GW; Zabetakis PM; Gardenswartz MH; Michelis MF Medicine (Baltimore); 1992 Sep; 71(5):284-90. PubMed ID: 1522804 [TBL] [Abstract][Full Text] [Related]
27. Effect Modifying Role of Serum Calcium on Mortality-Predictability of PTH and Alkaline Phosphatase in Hemodialysis Patients: An Investigation Using Data from the Taiwan Renal Registry Data System from 2005 to 2012. Lin YC; Lin YC; Hsu CY; Kao CC; Chang FC; Chen TW; Chen HH; Hsu CC; Wu MS; PLoS One; 2015; 10(6):e0129737. PubMed ID: 26107510 [TBL] [Abstract][Full Text] [Related]
28. Hysteresis of the parathyroid hormone response to hypocalcemia in hemodialysis patients with low turnover aluminum bone disease. Felsenfeld AJ; Ross D; Rodriguez M J Am Soc Nephrol; 1991 Dec; 2(6):1136-43. PubMed ID: 1777594 [TBL] [Abstract][Full Text] [Related]
29. Bisphosphonate kinetics in patients undergoing continuous ambulatory peritoneal dialysis: relations to dynamic bone histomorphometry, osteocalcin and parathyroid hormone. Joffe P; Hyldstrup L; Heaf JG; Pødenphant J; Henriksen JH Am J Nephrol; 1992; 12(6):419-24. PubMed ID: 1292341 [TBL] [Abstract][Full Text] [Related]
30. Secondary hyperparathyroidism among Nigerians with chronic kidney disease. Gimba ZM; Abene EE; Agbaji OOO; Agaba EI Afr Health Sci; 2018 Jun; 18(2):446-457. PubMed ID: 30602972 [TBL] [Abstract][Full Text] [Related]
31. Low dialysate calcium in continuous ambulatory peritoneal dialysis: a randomized controlled multicenter trial. The Peritoneal Dialysis Multicenter Study Group. Weinreich T; Passlick-Deetjen J; Ritz E Am J Kidney Dis; 1995 Mar; 25(3):452-60. PubMed ID: 7872324 [TBL] [Abstract][Full Text] [Related]
32. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. Grzegorzewska AE; Mlot M Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316 [TBL] [Abstract][Full Text] [Related]
33. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure. Fernández E; Amoedo ML; Montoliu J Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207 [TBL] [Abstract][Full Text] [Related]
34. Imaging of bone in the diagnostics of renal osteodystrophy in children with chronic renal failure. Ziółkowska H; Pańczyk-Tomaszewska M; Majkowska Z; Rajkowski T; Debiński A; Przedlacki J; Sawicki A; Ostrowski K; Marciński A; Roszkowska-Blaim M Med Sci Monit; 2001; 7(5):1034-42. PubMed ID: 11535955 [TBL] [Abstract][Full Text] [Related]
35. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599 [TBL] [Abstract][Full Text] [Related]
36. Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis. Laster M; Soohoo M; Streja E; Elashoff R; Jernigan S; Langman CB; Norris KC; Salusky IB; Kalantar-Zadeh K Pediatr Nephrol; 2019 Jan; 34(1):107-115. PubMed ID: 30267239 [TBL] [Abstract][Full Text] [Related]
37. Effect of haemodialysis on markers of bone turnover in children. Waller S; Ridout D; Rees L Pediatr Nephrol; 2007 Apr; 22(4):586-92. PubMed ID: 17216258 [TBL] [Abstract][Full Text] [Related]
38. Prevalence and pattern of renal osteodystrophy in chronic hemodialysis patients: a cross sectional study of 103 patients. Buargub MA; Nabulsi MF; Shafeh TA Saudi J Kidney Dis Transpl; 2006 Sep; 17(3):401-7. PubMed ID: 16970264 [TBL] [Abstract][Full Text] [Related]
39. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate. Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088 [TBL] [Abstract][Full Text] [Related]
40. Serum leptin in dialysis renal osteodystrophy. Coen G; Ballanti P; Fischer MS; Balducci A; Calabria S; Colamarco L; Di Zazzo G; Lifrieri F; Manni M; Sardella D; Nofroni I; Bonucci E Am J Kidney Dis; 2003 Nov; 42(5):1036-42. PubMed ID: 14582047 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]